Protein binding of flucloxacillin in neonates

Therapeutic Drug Monitoring

Volumn 29, Issue 3, 2007, Pages 279-283

  Pullen, Joyce ^a   Stolk, Leo M L ^a   Degraeuwe, Pieter L J ^a   Van Tiel, Frank H ^a   Neef, Cees ^a   Zimmermann, Luc J I ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Albumin; Flucloxacillin; Infants; Protein binding; Therapeutic drug monitoring; Ultrafiltration

Indexed keywords

BILIRUBIN; CREATININE; FATTY ACID; FLUCLOXACILLIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDOMETACIN; SERUM ALBUMIN; TRIACYLGLYCEROL; TRIAMTERENE; ALBUMINOID; ANTIINFECTIVE AGENT;

ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN SEPSIS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TRIACYLGLYCEROL BLOOD LEVEL; ULTRAFILTRATION; BLOOD; CLINICAL TRIAL; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; METHODOLOGY; PREMATURITY; PROTEIN BINDING; SEPSIS;

ALBUMINS; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; FLOXACILLIN; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; PROTEIN BINDING; SEPSIS;

EID: 34447513695     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318063e30f     Document Type: Article

References (25)

1. Janknegt R. The treatment of staphylococcal infections with special reference to pharmacokinetic, pharmacodynamic and pharmacoeconomic considerations. Pharm World Sci. 1997;19:133-141.
2. Pullen J, Rozario de L, Stolk LML, et al. Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates. Ther Drug Monit. 2006;28:351-358.
3. Hoog de M, Mouton JW, Anker van den JN. New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonatal Med. 2005;10:185-194.
4. Herngren L, Ehrnebo M, Broberger U. Pharmacokinetics of free and total flucloxacillin in newborn infants. Eur J Clin Pharmacol. 1987;32:403-409.
5. Notarianni LJ. Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet. 1990;18:20-36.
6. Ullmann U. The binding of isoxazolyl penicillins to human serum proteins. Arzneimittelforschung. 1977;27:2136-2138.
7. Bergan T, Engeset A, Olszewski W. Does serum protein binding inhibit tissue penetration of antibiotics? Rev Infect Dis. 1987;9:713-718.
8. Zeitlinger MA, Sauermann R, Traunmüller F, et al. Impact of plasma protein binding on antimicrobial activity using time-killing curves. J Antimicrob Chemother. 2004;54:876-880.
9. Røder BL, Frimodt-Møller N, Espersen F, et al. Dicloxacillin and flucloxacillin: pharmacokinetics, protein binding and serum bactericidal titers in healthy subjects after oral administration. Infection. 1995;23:107-112.
10. Thijssen HHW, Wolters J. The metabolic disposition of flucloxacillin in patients with impaired kidney function. Eur J Clin Pharmacol. 1982;22:429-434.
11. Sutherland R, Croydon EAP, Rolinson GN. Flucloxacillin, a new isoxazolyl penicillin, compared with oxacillin, cloxacillin, and dicloxacillin. BMJ. 1970;4:455-460.
12. Anderson P, Bluhm G, Ehrnebo M, et al. Pharmacokinetics and distribution of flucloxacillin in pacemaker patients. Eur J Clin Pharmacol. 1985;27:713-719.
13. Herngren L, Ehrnebo M, Boréus LO. Drug distribution in whole blood of mothers and their newborn infants. Eur J Clin Pharmacol. 1982;22:351-358.
14. Craig WA, Suh B. Protein binding and the antimicrobial effects: methods for the determination of protein binding. In: Lorian V, ed. Antibiotics in Laboratory Medicine, 2nd ed. Baltimore: Williams & Wilkins; 1986: 500-504.
15. Millipore Corporation. Centrifree Micropartition Devices for in Vitro Diagnostic Use and MPS Micropartition Devices Not for Use in Diagnostic Procedures. Available at: www.millipore.com/userguides.nsf/docs/pr02272. Accessed April 12, 2006.
16. Vanholder R, Landschoot van N, de Smet R, et al. Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int. 1988;33:996-1004.
17. Cartlidge PHT, Rutter N. Serum albumin concentrations and oedema in the newborn. Arch Dis Child. 1986;61:657-660.
18. Depner TA, Gulyassy PF. Plasma protein binding in uremia: extraction and characterization of an inhibitor. Kidney Int. 1980;18:86-94.
19. Robertz GM, Dengler HJ. Endogenous ligand(s) decrease drug-protein binding in uremic sera: a fluorescence probe study. Klin Wochenschr. 1983;61:649-653.
20. McNamara PJ, Lalka D, Gibaldi M. Endogenous accumulation products and serum protein binding in uremia. J Lab Clin Med. 1981;98:730-740.
21. Gulyassy PF, Bottini AT, Stanfel LA, et al. Isolation and chemical identification of inhibitors of plasma ligand binding. Kidney Int. 1986;30:391-398.
22. Boobis SW. Alteration of plasma albumin in relation to decreased drug binding in uremia. Clin Pharmacol Ther. 1977;22:147-153.
23. Friedman LA, Lewis PJ. The effect of semisynthetic penicillins on the binding of bilirubin by neonatal serum. Br J Clin Pharmacol. 1980;9:61-65.
24. Bratlid D. Pharmacologic aspects of neonatal hyperbilirubinemia. Birth Defects. 1976;12:184-191.
25. Ehrnebo M, Agurell S, Jalling B, et al. Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. Eur J Clin Pharmacol. 1971;3:189-193.